Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.78 |
| ▸ | PGR | P06401 | 3/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | SHBG | P04278 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17326003 | 1.00 | ESR1 (0.78) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL19096138 | 0.91 | ESR1 (0.77) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL17318121 | 0.91 | ESR1 (0.77) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL4395173 | 0.91 | ESR1 (0.77) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL19123270 | 0.91 | ESR1 (0.77) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL6872679 | 0.91 | ESR1 (0.77) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL7875926 | 0.90 | ESR1 (0.72) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL4239106 | 0.90 | ESR1 (0.72) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL8931573 | 0.90 | ESR1 (0.74) | ESR1CYP3A4LMNANR3C1PGR | |
| SCHEMBL4389365 | 0.90 | ESR1 (0.77) | ESR1CYP3A4LMNANR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 635 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240123025-A1 | LIPOPEPTIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES | Ruprecht-Karls-Universität Heidelberg (DE) | 2024-04-18 | — | — | US | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | claimed |
| US-9359451-B2 | Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof | THE UAB RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | claimed |
| US-20150352125-A1 | Methods and Compositions for Treating Trauma-Hemorrhage Using Estrogen and Derivatives Thereof | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-12-10 | — | — | US | claimed |
| US-12622891-B2 | AMP-activated protein kinase activator | KYOTO PHARMACEUTICAL UNIVERSITY (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| US-12521358-B2 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent | RAQUALIA PHARMA INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12447165-B2 | Intratumoral vein-formation promoting agent | OSAKA UNIVERSITY (JP) | 2025-10-21 | — | — | US | disclosed |
| WO-2001030762-A1 | IMIDAZOL-4-YLMETHANOLS USE AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-0974584-A1 | FUSED RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | disclosed |
| US-6015789-A | LUTEINIZING HORMONE RELEASING HORMONE AGONIST AND A LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST IN COMBINATION, | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| EP-0906115-A1 | COMBINED USE OF GnRH AGONIST AND ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 1999-04-07 | — | — | EP | disclosed |
| EP-0819430-A1 | Inhibitor of tumor metastasis or recurrence | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-21 | — | — | EP | disclosed |
| WO-1997040846-A1 | COMBINED USE OF GnRH AGONIST AND ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | ESR1 188/4885CYP3A4 1458/4885LMNA 796/4885 |
| US-12622891-B2 | AMP-activated protein kinase activator | PRKAA1, PRKAG1, PRKAB1 | ESR1 3201/4885CYP3A4 4733/4885LMNA 2028/4885 |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, WEE1 | ESR1 4066/4885CYP3A4 3135/4885LMNA 1378/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | ESR1 3467/4885CYP3A4 752/4885LMNA 2675/4885 |
| US-20150352125-A1 | Methods and Compositions for Treating Trauma-Hemorrhage Using Estrogen and Derivatives Thereof | SHBG, ESR1, ESR2 | ESR1 2/4885CYP3A4 644/4885LMNA 466/4885 |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | CHEK1, CHEK2, PDCD1 | ESR1 3282/4885CYP3A4 4836/4885LMNA 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.